Catalyst
Slingshot members are tracking this event:
PDUFA for Keytruda(pembrolizumab) in treating patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have already received two or more lines of chemotherapy date set for Sept. 22, 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 22, 2017
Occurred Source:
http://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-keytruda-pembrolizumab-previously-treate
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Biologics License Application, Keytruda, Pembrolizumab
